Medical specialties

Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Anatomy, Medical specialties, Blood, Hematology, Cardiovascular physiology, Blood volume, Transfusion medicine, Intravascular volume status, Blood test, Blood plasma, Capillary

Oak Ridge, TN, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data published in the journal Critical Care showing Daxor’s unique BVA-100 diagnostic blood test provides insights into the pathophysiology of volume derangements and capillary distress in critically ill COVID-19 patients enabling improved care.

Key Points: 
  • The Research Letter titled Blood volume and albumin transudation in critically-ill COVID-19 patients studied the abnormal blood volume profiles in mechanically ventilated patients admitted to the ICU at a leading medical center in New York.
  • The data shows that COVID-19 patients suffer from significant capillary damage and blood volume deficits that care teams became aware of through the use of the Daxor BVA-100 blood test.
  • Daxors BVA test is the first and only diagnostic test cleared by FDA that offers insights into patients blood volume with a 98% accurate measure of plasma and red cell volume.
  • We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.

Editas Medicine Announces Second Quarter 2021 Results and Business Updates

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Gene therapy, Clinical medicine, Editas Medicine, Medical specialties, Sickle cell disease, Natural killer cell

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2021.

Key Points: 
  • EDIT-301 RUBY trial for sickle cell disease screening patients; first patient on track to be dosed by year-end
    CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2021.
  • Editas Medicine is continuing to advance preclinical studies for a highly differentiated, iPSC-derived natural killer (NK) cell medicine.
  • The $5.8 million increase was primarily attributable to increased manufacturing and clinical related costs during the second quarter of 2021.
  • ET to provide and discuss a corporate update and financial results for the second quarter 2021.

inTEST Thermal Solutions and C1D1 Labs Collaborate to Deliver Cost Effective Hydrocarbon Cooling Solutions for Cannabis Extraction

Retrieved on: 
Wednesday, August 4, 2021
Heating, ventilation, and air conditioning, Euphoriants, Cannabis, Cannabis smoking, Chiller, Applied sciences, Academic disciplines, Medical specialties

As the industry matures, cannabis manufacturers will need higher capacity cooling solutions to keep up with the increase in production demands.

Key Points: 
  • As the industry matures, cannabis manufacturers will need higher capacity cooling solutions to keep up with the increase in production demands.
  • Thermonics chillers are designed to handle the industrial scaling of solvent cooling and recovery times desired by cannabis extraction companies.
  • There is a specific need for carefully controlled temperature and cooling power at the cryogenic temperatures required for hydrocarbon extraction, remarked Alexander Barsky, Founder and President of C1D1 Labs.
  • C1D1 Labs is a recognized leader in providing extraction solutions and equipment to the cannabis industry.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)

Retrieved on: 
Wednesday, August 4, 2021
Covaxin, Bharat Biotech, Health care, Health, Medical specialties

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • Pursuant to an agreement with Bharat Biotech, Ocugen has the exclusive right to develop, manufacture, and commercialize COVAXIN, a vaccine candidate for COVID-19.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 4, 2021
Medical specialties, Branches of biology, Clinical medicine, Vaccination, Alpha-synuclein, Lewy body dementia, Vaccine, Parkinson's disease

LAUSANNE, Switzerland, Aug. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended June 30, 2021, and provided a corporate update.

Key Points: 
  • Announced an all-stock acquisition of Affiris portfolio of therapeutics targeting alpha-synuclein notably PD01, a clinically validated active vaccine candidate that places AC Immune at the forefront of Parkinsons disease drug development.
  • The study is currently under analysis and AC Immune plans to present the results at an international Alzheimer conference.
  • SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU.
  • Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.

ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Immunology, Canaccord Genuity, Autoimmune disease, Genuity, Sjögren syndrome, Autoimmunity

SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m.

Key Points: 
  • SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m.
  • A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com.
  • ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer.
  • ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Immunovia, Inc. Receives Final Approval to Begin Patient Testing with the IMMray® PanCan-d Test

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Gastrointestinal cancer, Pancreatic cancer, Cancer, Pancreas, Immunoproteomics, Medical specialties, Clinical medicine

Today, Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), announced that it has received final approval to begin patient testing for the IMMray PanCan-d test the first blood test on the market dedicated to the early detection of pancreatic cancer.

Key Points: 
  • Today, Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), announced that it has received final approval to begin patient testing for the IMMray PanCan-d test the first blood test on the market dedicated to the early detection of pancreatic cancer.
  • The IMMray PanCan-d test fulfills an unmet clinical need and our ambition is to make the test available to individuals in all the high-risk groups for pancreatic cancer.
  • As a first step, we will launch the test for the familial/hereditary high-risk group, said Patrik Dahlen, Immunovias CEO.
  • The IMMray PanCan-d test is the first product developed from Immunovias proprietary immunoproteomics-based technology platform, IMMray, that measures the immune systems response to diseases in the blood.

Hospital Acquired Infection Control Market Analysis Report 2021-2028 by Type (Equipment, Services, Consumables), by End User (Hospitals & ICUs, Ambulatory Surgical & Diagnostic Centers) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Infectious Diseases, Hospitals, Health, Health, Medical specialties, Infectious diseases, Epidemiology, Occupational safety and health, Healthcare-associated infections, Hospital-acquired infection, COVID-19, Infection prevention and control, Infection, Surgery

The "Hospital Acquired Infection Control Market Size, Share & Trends Analysis Report by Type (Equipment, Services, Consumables), by End User (Hospitals & ICUs, Ambulatory Surgical & Diagnostic Centers), by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hospital Acquired Infection Control Market Size, Share & Trends Analysis Report by Type (Equipment, Services, Consumables), by End User (Hospitals & ICUs, Ambulatory Surgical & Diagnostic Centers), by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The key factors driving the market growth include the rising incidence of Hospital Acquired Infections (HAIs), supportive government initiatives and the COVID-19 pandemic.
  • The demand for infection control equipment and consumables also stemmed from the need to stop the spread of COVID-19.
  • The company was merged into Getinge's Infection Control portfolio to expand its offerings in the business area of Surgical Workflows
    Chapter 3 Hospital Acquired Infection Control Market Variables, Trends & Scope

U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report 2021-2028: Focus on Fine-needle Aspiration, Core, Surgical, Skin Biopsy/Punch Biopsy - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, Oncology, Clinical medicine, Medicine, Biopsy, Medical specialties, Fine-needle aspiration, Liquid biopsy, Skin biopsy, Lymph node biopsy, Breast biopsy

The "U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report by Type (Fine-needle Aspiration, Core, Surgical, Skin Biopsy/Punch Biopsy), by Application, by Site, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report by Type (Fine-needle Aspiration, Core, Surgical, Skin Biopsy/Punch Biopsy), by Application, by Site, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The increasing usage of technologically advanced devices for the early detection of diseases is one of the key factors driving the market.
  • A significant transaction from tumor to liquid biopsy is anticipated to increase the adoption of this technique in the market.
  • For instance, in June 2021, Biocept, Inc. and Quest Diagnostics collaborated to offer NGS-based liquid biopsy testing for lung cancer diagnosis.

China Assisted Reproduction Market Insight Report, 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
General Health, Health, Family, Consumer, Articles, Fertility medicine, Medical specialties, Academic disciplines, Infertility, China, Reproduction, Assisted reproductive technology, Reproductive medicine

The "China Assisted Reproduction Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Assisted Reproduction Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • By the end of 2019, there were about 308 million women aged 21-49 in China, that is, about 38.5 million-46.2 million women of school age suffered from infertility.
  • To sum up, China's assisted reproductive industry has three characteristics: great market development potential, uneven distribution of assisted reproductive service resources, and strong dependence on imports of assisted reproductive medicines and instruments.
  • Great market development potential: 9.6 million infertile couples, with a market demand gap of 375.3 billion yuan to be met.